A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine

PURPOSE: This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen. MATERIALS AND METHODS: Patients with progressive disease after first-line cisplatin plus S-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Keun-Wook, Kim, Bum Jun, Kim, Mi-Jung, Han, Hye Sook, Kim, Jin Won, Park, Young Iee, Park, Sook Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512362/
https://www.ncbi.nlm.nih.gov/pubmed/27764906
http://dx.doi.org/10.4143/crt.2016.216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512362/
https://www.ncbi.nlm.nih.gov/pubmed/27764906
http://dx.doi.org/10.4143/crt.2016.216

Ejemplares similares